Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | PHASE2 | COMPLETED | 65 | — | — | Apr 27, 2015 | Apr 21, 2021 | May 18, 2023 | 1 | United States |
Using IMWG criteria: PR (partial response) noted as \>50% reduction of serum M-protein and reduction in 24hr urinary M-protein by \>90% or to \<200mg/24h; VgPR (very good partial response) noted as serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>90% reduction in serum M-protein plus urine M-protein level \<100mg/24h; CR (complete response) noted as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow; sCR (stringent complete response) noted as CR defined above plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| Arm | Type | Description |
|---|---|---|
| BeEAM | EXPERIMENTAL | Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma |
| Name | Type | Description |
|---|---|---|
| BeEAM | DRUG | BeEAM |
Inclusion Criteria: * Age between 18 - 70 years * Karnofsky status ≥ 70% * Diagnosis of Multiple Myeloma * Within 9 months of the start of induction chemotherapy and no evidence of relapse or progression. * Availability of Cryopreserved peripheral blood stem cells with a CD34 dose of at least 2x106...